Loading clinical trials...
Loading clinical trials...
A Phase II Trial of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
Conditions
Interventions
Cadonilimab
Lenvatinib
Locations
1
China
Sun Yat-sen University Cancer Cetntre
Guangzhou, China
Start Date
May 8, 2023
Primary Completion Date
July 31, 2025
Completion Date
June 30, 2026
Last Updated
March 10, 2026
NCT06340568
NCT06952504
NCT06257264
NCT06253494
NCT06547840
NCT05990426
Lead Sponsor
Sun Yat-sen University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions